Role of Lipoproteins in Carotid Arterial Disease

  • Efthymios D. Avgerinos
  • Christos D. LiapisEmail author


Lipoproteins and their disorders are among the most substantiated risk factors for atherosclerosis and cardiovascular diseases, acting through a well-established pathway: abnormalities in lipid metabolism lead to pathologic lipid accumulation in the vessel wall, oxidative and chronic inflammatory sequelae, and the formation of atherosclerotic lesions, ultimately leading to clinical events.


Carotid Stenosis Carotid Plaque Carotid Atherosclerosis Carotid Artery Disease Bile Acid Sequestrant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Goldberg AC. Section 8: Endocrine and metabolic disorders, Chapter 100: Lipid disorders. In: Porter RS, Kaplan JL, editors. The Merck manual of diagnosis and therapy. 19th ed. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2011.Google Scholar
  2. 2.
    Ridker P, Libby P. Chapter 44: Risk markers for atherothrombotic disease. Genest J, Libby P. Chapter 47: Lipoprotein disorders and cardiovascular disease. In: Bonow RO, Mann D, Zipes D, Libby P, editors. Braunwald’s heart disease: a textbook of cardiovascular medicine. 9th ed. Philadelphia: Saunders; 2012.Google Scholar
  3. 3.
    Liapis CD. Chapter 25: Atherosclerosis risk factor treatment – general considerations. Walcott R, Howard J. Chapter 28: Atherosclerotic risk factors – hyperlipidemia. In: Cronenwett JL, Johnston W, editors. Rutherford’s vascular surgery. 7th ed. Philadelphia: W.B. Saunders; 2010.Google Scholar
  4. 4.
    Lamon BD, Haijar DP. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol. 2008;173:1253–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Napoli C, De Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem. 2001;82:674–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Matsunaga T. Modulation of reactive oxygen species in endothelial cells by peroxynitrite-treated lipoproteins. J Biochem. 2001;130:285–93.PubMedCrossRefGoogle Scholar
  7. 7.
    Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med. 1992;43:219–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Flavahan NA. Atherosclerosis or lipoprotein induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 1992;85:1927.PubMedCrossRefGoogle Scholar
  10. 10.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRefGoogle Scholar
  11. 11.
    SPARCL Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.CrossRefGoogle Scholar
  12. 12.
    Sillesen H, Amarence P, Hennerici MG. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis. A secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39:3297.PubMedCrossRefGoogle Scholar
  13. 13.
    Sigala F, Kotsinas A, Savari P, et al. Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability. J Vasc Surg. 2010;52:704–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Uno M, Kitazato KT, Suzue A, Itabe H, Hao L, Nagahiro S. Contribution of an imbalance between oxidant-antioxidant systems to plaque vulnerability in patients with carotid artery stenosis. J Neurosurg. 2005;103:518–22.PubMedCrossRefGoogle Scholar
  15. 15.
    Wallenfeldt K, Fegerberg B, Wkstrand J, et al. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med. 2004;256:413–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Mackey RH, Kuller LH, Sutton-Tyrrell K, et al. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. Am J Cardiol. 2002;90:71i–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Koba S, Hirano T, Kondo T, et al. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am Heart J. 2002;144:1026–35.PubMedCrossRefGoogle Scholar
  18. 18.
    Skoglund-Andersson C, Tang R, Bond MG, et al. LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men. Arterioscler Thromb Vasc Biol. 1999;19:2422–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Liu ML, Ylitalo K, Nuotio I, et al. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke. 2002;33:1255–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Norata GD, Raselli S, Grigore L, Garlaschelli K, et al. Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Atherosclerosis. 2009;206:556–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Shoji T, Hatsuda S, Tsuchikura A, et al. Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis. 2009;202:582–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Hodis HJ, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol. 1995;6:209–14.PubMedCrossRefGoogle Scholar
  23. 23.
    Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95:2022–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Kofoed SC, Gronholdt ML, Bismuth J, et al. Echolucent, rupture-prone carotid plaques associated with elevated triglyceride-rich lipoproteins, particularly in women. J Vasc Surg. 2002;36:783–92.PubMedGoogle Scholar
  25. 25.
    Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352–64.PubMedCrossRefGoogle Scholar
  26. 26.
    Barter PJ, Nicholls S, Raye KA, et al. Antiinflammatory properties of HDL. Circ Res. 2004;95:764–72.PubMedCrossRefGoogle Scholar
  27. 27.
    Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003;34:623–31.PubMedCrossRefGoogle Scholar
  28. 28.
    Koren-Morag N, Tanne D, Graff E, et al. Low- and high density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch Intern Med. 2002;162:993–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001;285:2729–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis. 2008;196:489–96.PubMedCrossRefGoogle Scholar
  31. 31.
    Liapis CD, Avgerinos ED, et al. What a vascular surgeon should know and do about atherosclerotic risk factors. J Vasc Surg. 2009;49:1348–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Stalenhoef AFH, Graaf J. Association of fasting and non fasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol. 2008;19:355–61.PubMedCrossRefGoogle Scholar
  33. 33.
    Stalenhoef AF, Casparie AF, Demacker PN, et al. Combined deficiency of apolipoprotein C-II and lipoprotein lipase in familial hyperchylomicronemia. Metabolism. 1981;30:919–26.PubMedCrossRefGoogle Scholar
  34. 34.
    Frick MH, EIo O, Haapa K. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–45.PubMedCrossRefGoogle Scholar
  35. 35.
    Rubins HB, Robins SJ, Collins D, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556–63.PubMedCrossRefGoogle Scholar
  37. 37.
    Labreuche J, Deplanque D, Touboul PJ, et al. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis systematic review and meta-regression analysis. Atherosclerosis. 2010;212:9–15.PubMedCrossRefGoogle Scholar
  38. 38.
    Miles LA, Fless GM, Levin EG, et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989;339:301–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Fortunato JE, Bassiouny HS, Song RH, et al. Apolipoprotein(a) fragments in relation to human carotid plaque instability. J Vasc Surg. 2000;32:555–63.PubMedCrossRefGoogle Scholar
  40. 40.
    Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke. Stroke. 2007;38:1959–66.PubMedCrossRefGoogle Scholar
  41. 41.
    Epps KC, Wilensky RL. Lp-PLA2 – a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med. 2011;269:94–106.PubMedCrossRefGoogle Scholar
  42. 42.
    Stafforini DM, McIntyre TM, Carter ME. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein ­particles and role in the degradation of plateletactivating factor. J Biol Chem. 1987;262:4215–22.PubMedGoogle Scholar
  43. 43.
    Mannheim D, Herrmann J, Versari D, et al. Enhanced expression of Lp-PLA2 and lyso PC hosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke. 2008;39:1448–55.PubMedCrossRefGoogle Scholar
  44. 44.
    Vickers KC, Maguire C, Wolfert RL, et al. Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis. J Lipid Res. 2009;50:1735–43.PubMedCrossRefGoogle Scholar
  45. 45.
    Tsimikas S, Willeit J, Knoflach M, et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J. 2009;30:107–15.PubMedCrossRefGoogle Scholar
  46. 46.
    Oei HH, van der Meer IM, Hofman A. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Persson M, Berglund G, Nelson JJ, Hedblad B. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmo, Sweden. Atherosclerosis. 2008;200:191–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Elkind MS, Tai W, Coates K, et al. Lipoprotein associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis. 2009;27:42–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Gardener H, Morte DD, Elkind MSV, et al. Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). BMC Cardiovasc Disord. 2009;9:55.PubMedCrossRefGoogle Scholar
  50. 50.
    Enomoto M, Adachi H, Hirai Y. LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone. J Lipids. 2011. doi: 10.1155/2011/549137.
  51. 51.
    Bang OY, Saver JL, Liebeskind DS, et al. Association of serum lipid indices with large artery atherosclerotic stroke. Neurology. 2008;70:841–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Kang K, Lee K, Chung SH. The triglyceride:high-density lipoprotein-cholesterol ratio and steno-occlusive disease in the intracranial arteries. J Thromb Thrombolysis. 2011;32:103–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Boizel R, Benhamou PY, Lardy B, et al. Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. Diabetes Care. 2000;23:1679–85.PubMedCrossRefGoogle Scholar
  54. 54.
    Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34:583–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.CrossRefGoogle Scholar
  56. 56.
    Grundy SM, Cleeman JI, Merz CN, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.PubMedCrossRefGoogle Scholar
  57. 57.
    Liapis CD, Bell PR, Mikhailidis D, ESVS Guidelines Collaborators. ESVS guidelines. Section A -Prevention in patients with carotid artery stenosis. Curr Vasc Pharmacol. 2010;8:673–81.PubMedCrossRefGoogle Scholar
  58. 58.
    Ricotta JJ, Aburahma A, Ascher E, et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease: executive summary. J Vasc Surg. 2011;54:832–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Brott TG, Halperin JL, Abbara S. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Circulation. 2011;124:e54–130.PubMedCrossRefGoogle Scholar
  60. 60.
    Crisby M, Nordin-Fredriksson G, Shah PK. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. implications for plaque stabilization. Circulation. 2001;103:926–33.PubMedCrossRefGoogle Scholar
  61. 61.
    Taylor AJ, Flaherty PJ. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055–60.PubMedCrossRefGoogle Scholar
  62. 62.
    Avgerinos ED, Kadoglou NPE, Moulakakis K, Giannakopoulos T, Liapis C. Current role of biomarkers in carotid disease: a systematic review? Int J Stroke. 2011;6:337–45.PubMedCrossRefGoogle Scholar
  63. 63.
    Kunte H, Amberger N, Busch MA, Rückert RI, Meiners S, Harms L. Markers of instability in high-risk carotid plaques are reduced by statins. J Vasc Surg. 2008;47:513–22.PubMedCrossRefGoogle Scholar
  64. 64.
    Kadoglou NP, Gerasimidis T, Moumtzouoglou A, et al. Intensive lipid lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. Eur J Vasc Endovasc Surg. 2008;35:661–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Kadoglou NP, Gerasimidis T, Kapelouzou A, et al. Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid lowering therapy in patients with bilateral carotid stenosis. Eur J Vasc Endovasc Surg. 2010;39:258–65.PubMedCrossRefGoogle Scholar
  66. 66.
    Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima – media thickness. N Eng J Med. 2009;361:2113–22.CrossRefGoogle Scholar
  67. 67.
    Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–43.PubMedCrossRefGoogle Scholar
  68. 68.
    Bloomfield Rubins H, Davenport J, Babikian V, VA-HIT Study Group. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828–33.PubMedCrossRefGoogle Scholar
  69. 69.
    Balk E, Chung M, Lichtenstein A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evidence report/technology assessment no. 93. Rockville: Agency for Healthcare Research and Quality; 2004.Google Scholar
  70. 70.
    Lorenz MW, von Kegler S, Steinmetz H, et al. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the carotid atherosclerosis progression study (caps). Stroke. 2006;37:87–92.PubMedCrossRefGoogle Scholar
  71. 71.
    Florentin M, Liberopoulos EN, Mikhailidis DP, et al. Emerging options in the treatment of dyslipidemias: a bright future? Expert Opin Emerg Drugs. 2011;16:247–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of Vascular Surgery, Medical School of AthensAttikon University HospitalAthensGreece

Personalised recommendations